Author

Cecile Oblette

Observed name: C. Oblette

ORCID: 0009-0000-5200-8002

Observed ORCID: 0009-0000-5200-8002

OpenAlex ID: A5046721403

Abstract 5085: Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b

2024 · Elizabeth Horsley, Asma Jabeen, et al. · Cancer Research · 4

Abstract 3122: Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6

2024 · Nicola Tsang, Nicolas Veillard, et al. · Cancer Research · 3

Abstract 6736: Preclinical development of ADCT-241, a novel exatecan-based antibody-drug conjugate targeting PSMA for the treatment of prostate cancer

2025 · Ben Leatherdale, Beccie Martin, et al. · Cancer Research · 2

Abstract 1604: Preclinical development of ADCT-211, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting solid tumors expressing IL13RA2

2023 · Francesca Zammarchi, Karin Havenith, et al. · Cancer Research · 2

Preclinical Characterization of ADCT-241, an Exatecan-Based Antibody–Drug Conjugate against PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer

2026 · Asma Jabeen, Ben Leatherdale, et al. · Molecular Cancer Therapeutics

171 (PB159): Preclinical characterization of NaPi2b-PL2202, a novel exatecan-based antibody drug conjugate

2024 · A. Jabeen, N. Janghra, et al. · European Journal of Cancer

Works count: 6

Citation count: 11

H-index: 2

I10-index: